Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,770 matching trials from the live ClinicalTrials.gov search.
Conditions
Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Interventions
HBI-8000 in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Port Saint Lucie, Florida + 3 more
Conditions
Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
Interventions
MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Drug
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Conditions
Solid Tumors, Non-Small Cell Lung Cancer (NSCLC)
Interventions
Panobinostat, Cisplatin, Pemetrexed
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Sacramento, California • Detroit, Michigan
Conditions
Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Interventions
Pembrolizumab, FF-10832
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
23
States / cities
Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Conditions
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions
AZD0022, Cetuximab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Duarte, California • New York, New York • Fairfax, Virginia
Conditions
Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Sotorasib, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
27
States / cities
Santa Barbara, California • Newark, Delaware • Coral Springs, Florida + 23 more
Conditions
Neoplasms
Interventions
Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more
Conditions
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma
Interventions
Antiretroviral Therapy, Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Positron Emission Tomography
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 6 more
Conditions
Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lung Cancer
Interventions
lomustine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Carcinoma, Non-Small Cell, Neoplasm Metastasis
Interventions
PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Amherst, New York • Buffalo, New York • San Antonio, Texas
Conditions
Non-Small Cell Lung Cancer, Urothelial Cancer
Interventions
Avelumab (MSB0010718C), Axitinib (AG-013736)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Glendale, Arizona • Goodyear, Arizona • Phoenix, Arizona + 8 more
Conditions
Non-Small Cell Lung Cancer
Interventions
MEDI4736
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
28
States / cities
Goodyear, Arizona • Santa Rosa, California • New Haven, Connecticut + 22 more
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer
Interventions
CKD-703
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
19 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ohio City, Ohio
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
CC-486, Pembrolizumab, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
10
States / cities
Glendale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Conditions
Non-small Cell Lung Cancer
Interventions
Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Conditions
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
nintedanib
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Conditions
Advanced Solid Tumor
Interventions
BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Conditions
Advanced NSCLC
Interventions
REGN5093-M114, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Orange, California • Denver, Colorado • Baltimore, Maryland + 7 more
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Oakland, California • Roseville, California • San Francisco, California + 13 more
Conditions
Adenocarcinoma of Lung, Lung Cancer
Interventions
Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed, Placebo
Drug · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more
Conditions
Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
Interventions
AMG 794
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Orange, California + 1 more